Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid in patients undergoing total hip and total knee arthroplasty: No increased risk of bleeding

Summary

Patients undergoing total hip or knee arthroplasty should receive anticoagulant therapy because of the high risk of venous thromboembolism. However, many are already taking non-steroidal anti-inflammatory drugs (NSAIDs) or acetylsalicylic acid (ASA) that can have antihaemostatic effects. We assessed the bleeding risk in patients treated with thromboprophylactic dabigatran etexilate, with and without concomitant NSAID or ASA. A post-hoc analysis was undertaken of the pooled data from trials comparing dabigatran etexilate (220 mg and 150 mg once daily) and enoxaparin. Major bleeding event (MBE) rates were determined and odds ratios (ORs) generated for patients who received study treatment plus NSAID (half-life ≤12 hours) or ASA (≤160 mg/day) versus study treatment alone. Relative risks were calculated for comparisons between treatments. Overall, 4,405/8,135 patients (54.1%) received concomitant NSAID and 386/8,135 (4.7%) received ASA.ORs for the comparison with/without concomitant NSAID were 1.05 (95% confidence interval [CI] 0.55–2.01) for 220 mg dabigatran etexilate; 1.19 (0.55–2.55) for 150 mg; and 1.32 (0.67–2.57) for enoxaparin. ORs for the comparison with/without ASA were 1.14 (0.26–5.03); 1.64 (0.36–7.49); and 2.57 (0.83–7.94), respectively. For both NSAIDs and ASA there was no significant difference in bleeding between patients with and without concomitant therapy in any treatment arm. Patients concomitantly taking NSAIDs or ASA have a similar risk of MBE to those taking dabigatran etexilate alone. No significant differences in MBE were detected between dabigatran etexilate and enoxaparin within comedication subgroups, suggesting that no increased major bleeding risk exists when dabigatran etexilate is administered with NSAID or ASA.

Investigation performed at multiple centres participating in the RE-MODEL™, RE-NOVATE®, and RE-MOBILIZE® trials.

Keywords

Oral - dabigatran etexilate - non-steroidal anti-inflammatory drugs - ASA - bleeding

• References

• 1 McNally MA, Mollan RAB. Venous thromboembolism and orthopaedic surgery. J Bone Joint Surg Br 1993; 75-B: 517-519.
• 2 Geerts WH, Bergqvist D, Pineo GF. et al. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 2008; 133: 381-453S.
• 3 Turpie AG, Esmon C. Venous and arterial thrombosis - pathogenesis and the rationale for anticoagulation. Thromb Haemost 2011; 105: 586-596.
• 4 Zhang W, Moskowitz RW, Nuki G. et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008; 16: 137-162.
• 5 Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002; 324: 71-86.
• 6 Dahl OE, Ögren M, Agnelli G. et al. Assessment of bleeding after concomitant administration of antiplatelet and anticoagulant agents in lower limb arthroplasty. Pathophysiol Haemost Thromb 2006; 35: 428-434.
• 7 Robinson CM, Christie J, Malcolm-Smith N. Nonsteroidal antiinflammatory drugs, perioperative blood loss, and transfusion requirements in elective hip arthroplasty. J Arthroplasty 1993; 08: 607-610.
• 8 Slappendel R, Weber EW, Benraad B. et al. Does ibuprofen increase perioperative blood loss during hip arthroplasty?. Eur J Anaesthesiol 2002; 19: 829-831.
• 9 Fischer HB, Simanski CJ. A procedure-specific systematic review and consensus recommendations for analgesia after total hip replacement. Anaesthesia 2005; 60: 1189-1202.
• 10 Macie C, Forbes L, Foster GA. et al. Dosing practices and risk factors for bleeding in patients receiving enoxaparin for the treatment of an acute coronary syndrome. Chest 2004; 125: 1616-1621.
• 11 Lotke PA, Lonner JH. Deep venous thrombosis prophylaxis: better living through chemistry – in opposition. J Arthroplasty 2005; 20 (Suppl. 02) 15-17.
• 12 Guijarro R, Montes J, San Román C. et al. Venous thromboembolism and bleeding after total knee and hip arthroplasty. Findings from the Spanish National Discharge Database. Thromb Haemost 2011; 105: 610-615.
• 13 Schulman S, Beyth RJ, Kearon C. et al. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians evidencebased clinical practice guidelines (8th Edition). Chest 2008; 133: 257-298S.
• 14 Pola E, Papaleo P, Santoliquido A. et al. Clinical factors associated with an increased risk of perioperative blood transfusion in nonanemic patients undergoing hip arthroplasty. J Bone Joint Surg Am 2004; 86: 57-61.
• 15 Health Canada Drug Product Database. Available at: http://webprod3.hc-sc.gc.ca/dpd-bdpp/info.do?lang=eng&code=79794 Accessed October 21, 2011.
• 16 European Medicines Agency. Pradaxa. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/ 000829/human_med_000981.jsp&jsenabled=false Accessed October 21, 2011.
• 17 Eriksson BI, Dahl OE, Rosencher N. et al. RE-MODEL Study Group. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007; 05: 2178-2185.
• 18 Eriksson BI, Dahl OE, Rosencher N. et al. RE-NOVATE Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007; 370: 949-956.
• 19 RE-MOBILIZE Writing Committee. Ginsberg JS, Davidson BL. et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty. J Arthroplasty 2009; 24: 1-9.
• 20 The European Agency for the Evaluation of Medicinal Products. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003301.pdf Accessed September 2, 2010.
• 21 Eriksson BI, Dahl OE, Büller HR. et al. BISTRO II Study Group. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost 2005; 03: 103-111.
• 22 Hull RD, Pineo GF, Francis G. et al. for the North American Fragmin Trial Investigators. Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients. A double-blind, randomized comparison. Arch Intern Med 2000; 160: 2199-2207.
• 23 Turpie AGG, Bauer KA, Eriksson BI. et al. for the Steering Committees of the Pentasaccharide Orthopedic Prophylaxis Studies. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery. A meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002; 162: 1833-1840.
• 24 Eikelboom JW, Wallentin L, Connolly SJ. et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation. An analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) Trial. Circulation 2011; 123: 2363-2372.
• 25 Dans AL, Connolly S, Bruckmann M. et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the randomized evaluation of long-term anti-coagulation therapy (RELY®) trial. Presented at the 33^rd Congress of the European Society of Cardiology (ESC), Paris. 27–31 Aug 2011 Available at: http://www.escardio.org/congresses/esc-2011/congress-reports/Pages/709-S-RE-LY.aspx Accessed April 25, 2012.
• 26 AstraZeneca. 2006 AstraZeneca decides to withdraw Exanta™. Available at: http://www.astrazeneca.com/media/latest-press-releases/2006/5217?itemId=3891692 Accessed September 2, 2010.